An Open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response

Condition: advanced solid tumors with genomic alterations or protein expression patterns predictive of response

Sponsor: Roche-Genetech

An Open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response. MyTACTIC is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in patients with advanced unresectable or metastatic solid tumors determined to harbor specific biomarkers.


Go To Trial Homepage